Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Top Stories > MAGNA Pharmaceuticals Selects LSPediA for DSCSA Serialization

MAGNA Pharmaceuticals Selects LSPediA for DSCSA Serialization

Published by Gbaf News

Posted on August 7, 2018

3 min read

Last updated: January 21, 2026

GAC reprimands Stellantis over joint venture plans in China - Global Banking & Finance Review — The image illustrates the tense relationship between Guangzhou Automobile Group (GAC) and Stellantis over the proposed increase in stake for their joint venture, highlighting the complexities of foreign investment in China's automotive market.

LSPediA, a leading software and service provider for the pharmaceutical industry, today announced a new business relationship with MAGNA Pharmaceuticals.

MAGNA specializes in supplying high-quality prescription and consumer products to health care providers contracted under the U.S. Department of Veterans Affairs and the civilian market. Meeting federal and state compliance requirements is a proud tradition and a non-negotiable commitment for MAGNA.

The 10-year vision of the FDA’s 2013 Drug Supply Chain Security Act enforces new and stringent requirements to strengthen the U.S. drug supply chain and eradicate drug counterfeiting.

“Patient safety is paramount in our mission, in addition to providing efficacious and affordable products/services for patients and other health care stakeholders,” said Warren Lesser, Ph.D., CEO of MAGNA Pharmaceuticals. “Partnering with LSPediA enables DSCSA compliance and augments our supply chain operations. The cloud technology and RF mobile scanners automate our processes to quickly trade and distribute serialized products with 100% accuracy, contributing to overall health care delivery.”

By leveraging RxChain®, MAGNA Pharmaceuticals enables Track and Trace, Serialization, shipment aggregation, and seamless data exchange with trading partners and provides full FDA DSCSA compliance now and for the future.

“Our software is built for companies like MAGNA to advance supply chain and meet compliance,” said Riya Cao, LSPediA CEO. “RxChain®’s Cloud Solution, mobile technology, and best-in-practice workflow serve as a robust serialization platform for MAGNA’s daily operations. When we take on the heavy lifting of compliance and serialization, our customers can focus on their core business and flourish.”

LSPediA, a leading software and service provider for the pharmaceutical industry, today announced a new business relationship with MAGNA Pharmaceuticals.

MAGNA specializes in supplying high-quality prescription and consumer products to health care providers contracted under the U.S. Department of Veterans Affairs and the civilian market. Meeting federal and state compliance requirements is a proud tradition and a non-negotiable commitment for MAGNA.

The 10-year vision of the FDA’s 2013 Drug Supply Chain Security Act enforces new and stringent requirements to strengthen the U.S. drug supply chain and eradicate drug counterfeiting.

“Patient safety is paramount in our mission, in addition to providing efficacious and affordable products/services for patients and other health care stakeholders,” said Warren Lesser, Ph.D., CEO of MAGNA Pharmaceuticals. “Partnering with LSPediA enables DSCSA compliance and augments our supply chain operations. The cloud technology and RF mobile scanners automate our processes to quickly trade and distribute serialized products with 100% accuracy, contributing to overall health care delivery.”

By leveraging RxChain®, MAGNA Pharmaceuticals enables Track and Trace, Serialization, shipment aggregation, and seamless data exchange with trading partners and provides full FDA DSCSA compliance now and for the future.

“Our software is built for companies like MAGNA to advance supply chain and meet compliance,” said Riya Cao, LSPediA CEO. “RxChain®’s Cloud Solution, mobile technology, and best-in-practice workflow serve as a robust serialization platform for MAGNA’s daily operations. When we take on the heavy lifting of compliance and serialization, our customers can focus on their core business and flourish.”